hb0025
mAbexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2021 (NCT04678908)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
FLT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06758557 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2024 | Huabo Biopharm Co., Ltd., Huazhong University of Science and Technology, Sun Yat-Sen University, Zhejiang Huahai Pharmaceutical Co., Ltd. |
| NCT06222125 | Phase 2 | Jan 30, 2023 | Fudan University, Huabo Biopharm Co., Ltd. |
| NCT04678908 | Phase 1 | Mar 8, 2021 | Huabo Biopharm Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huabo Biopharm Co., Ltd. | For profit | 3 | 3 | 2 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | For profit | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1